November 10-11 | In-Person & Digital (London)

GLOBAL PHARMA AND BIOTECH SUMMIT

Save 10% as an Endpoints reader with code EP10

China’s share of new drug candidates entering trials went from 8% in 2018 to 30% in 2025.* Licensing was the early story. Western biotechs are no longer competing on the same terms.

Chinese developers move faster and spend less. The hard question for pharma companies is what to do about it: match them on speed, partner with them or write off the categories where they get there first. And when the data come back, how do you judge their quality and global acceptability without treating them as a simple yes or no?

The Global Pharma and Biotech Summit, presented by the Financial Times in collaboration with Endpoints News, puts that to the dealmakers and R&D leaders living it. Sessions cover what makes partnerships with Chinese companies work, what role Europe plays and what it takes for Chinese drugmakers to build global blockbusters. Join us in London or online.

Save 10% as an Endpoints reader with code EP10
Want the full agenda? Download the event brochure.

*From the Financial Times report “China’s biotech boom,” published June 2026.